IGEN BIOLAB GROUP is a pioneer biotech company in the development of microbiome modulators, which are bioactive therapeutics that benefit human health by altering the composition and activities of the microbial communities in the body to regulate host pathways.

IGEN BIOLAB GROUP´s focus is on microbiome modulators that impact on infection, immunity and metabolic disease. The company is currently pursuing clinical studies and additional researches. Recent scientific discoveries are forcing the industry to rethink how changes in the microbiome influence human health, and IGEN BIOLAB GROUP is among the first companies translating microbiome discoveries.


IGEN BIOLAB GROUP is pioneering a path for commercial development in this untapped area.

Published microbiome researches make clear that human microbiome is a fundamental component of human physiology. Changes in the microbiome can cause changes to human cellular activities that result in disease or contribute to its progression. Unlike traditional discovery efforts that have focused on the human side of the equation, IGEN BIOLAB GROUP believes that therapeutic product breakthroughs can be made by focusing on how the microbiota interacts with itself and with its human host to impact health and disease.

IGEN BIOLAB GROUP has developed a proprietary approach for generating small molecule, peptide biologic, and symbiotic product candidates that modulate microbe and microbe-human interactions that contribute to health or disease. This approach is based on understanding microbial community composition and function in healthy and diseased conditions. These profiles also form the basis for the discovery of novel biomarkers used for the development of novel drugs and diagnostics.


IGEN BIOLAB GROUP is engaged in a number of strategic collaborations for the discovery and development of microbiome modulating therapeutics. These partnerships further validate the broad utility of IGEN BIOLAB GROUP Microbiome Science capabilities to develop product candidates  across multiple disease areas.

IGEN BIOLAB GROUP works with a broad network of researchers—from academic laboratories to multinational bio pharma and nutrition companies—to support discovery aimed at identifying novel disease targets and mechanisms. IGEN BIOLAB GROUP unique set of microbiome science capabilities and toolkits leverage comprehensive metagenomic assay expertise, validated SOPs for bio-specimen sample handling and genomic preparation, as well as integrated bioinformatic pipelines. 

Contact Us